SynthesisFrontiers in immunology2026
Efficacy, safety, and PD-L1-defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant immune checkpoint inhibitors combined with chemotherapy improve pathological complete response in early-stage triple-negative breast cancer, but the consistency of benefit, role of PD-L1 expression, and immune-related toxicity remain clinically relevant. Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to June 30, 2026, for randomized trials comparing neoadjuvant immune checkpoint inhibitors plus chemotherapy with chemotherapy alone or placebo plus chemotherapy in early-stage triple-negative breast cancer. The primary efficacy analysis was restricted to phase III trials. Risk ratios and 95% confidence intervals were pooled using a random-effects model. Risk of bias and certainty of evidence were assessed using RoB 2 and GRADE. Results: Four phase III trials including 3,377 patients were included in the primary efficacy synthesis. Neoadjuvant immune checkpoint inhibitors plus chemotherapy significantly increased pathological complete response compared with control treatment (risk ratio, 1.27; 95% confidence interval, 1.19-1.36; P < 0.001), with no statistical heterogeneity. Benefit was observed in both PD-L1-positive tumors (risk ratio, 1.32; 95% confidence interval, 1.18-1.48) and PD-L1-negative tumors (risk ratio, 1.45; 95% confidence interval, 1.22-1.72). Grade ≥ 3 treatment-related adverse events were not significantly increased (risk ratio, 1.06; 95% confidence interval, 0.98-1.13), whereas immune-related adverse events were more frequent with immune checkpoint inhibitors (risk ratio, 3.52; 95% confidence interval, 1.88-6.57). Conclusions: Neoadjuvant immune checkpoint inhibitors plus chemotherapy improve pathological complete response in early-stage triple-negative breast cancer, including across PD-L1-defined subgroups, but increase immune-related toxicity. PD-L1 expression alone appears insufficient for treatment selection. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard#, identifier CRD420261412366.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.